Please assess the completion status of the following clinical trial:

Trial Title: Pazopanib Maintenance Phase II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up~* Patients must have histological evidence of high-grade soft tissue sarcoma (grade 2 - 3) according to the FNLCC grading system, tumor size ≥ 5 cm and deep localization with regard to the superficial fascia, excluding the following tumor types:~  * Embryonal rhabdomyosarcoma~ * Chondrosarcoma (excluding extraskeletal myxoid chondrosarcoma)~ * Osteosarcoma (excluding extraskeletal osteosarcoma)~ * Ewing tumors / primitive neuroectodermal tumor (PNET)~ * Gastro-intestinal stromal tumors (GIST)~ * Dermatofibrosarcoma protuberans~* Patients who had undergone previous surgery with inadequate margins (tumour-free margins ≤1 cm or margins contaminated) are eligible if thermochemotherapy has been started within 8 weeks after surgery~* Unstained slides and ideally tumour blocks must be available for histological central review~* Completed 4 to 8 cycles of thermochemotherapy with doxorubicin and ifosfamide at least 21 days but no more than 42 days prior to study entry~* No evidence of disease following completion of first-line thermochemotherapy and within ≤ 21 days of study entry~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* No other prior chemotherapy except thermochemotherapy with doxorubicin and ifosfamide~* Adequate organ system function~Exclusion Criteria:~* No prior or concurrent second primary malignant tumors (except adequately treated in situ carcinoma of cervix, or basal cell carcinoma)~* No symptomatic or known Central nervous system (CNS) metastases at baseline~* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:~  * Active peptic ulcer disease~ * Known intraluminal metastatic lesion/s with risk of bleeding~ * Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn's disease), or other gastrointestinal conditions with increased risk of perforation~ * History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.~* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:~  * Malabsorption syndrome~ * Major resection of the stomach or small bowel.~* Corrected QT interval (QTc) \> 480 msecs~* History of any one or more of the following cardiovascular conditions within the past 6 months:~  * Cardiac angioplasty or stenting~ * Myocardial infarction~ * Unstable angina~ * Coronary artery bypass graft surgery~ * Symptomatic peripheral vascular disease~ * Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) (See Appendix D for description)~* Poorly controlled hypertension (SBP of ≤ 150 mmHg or DBP of ≤95 mmHg is acceptable provided that BP will be treated and monitored at least weekly. The goal is to attain controlled hypertension within 4 weeks of start of IMP which is defined as grade ≤1 hypertension CTCAE Version 4.0)~* NYHA II at Screening for Patients \> 65 years~* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.~Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible~* Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery).~* Evidence of active bleeding or bleeding diathesis.~* Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage Note: Lesions infiltrating major pulmonary vessels (contiguous tumour and vessels) are excluded; however, the presence of a tumor that is touching, but not infiltrating (abutting) the vessels is acceptable (CT with contrast is strongly recommended to evaluate such lesions).~  * Large protruding endobronchial lesions in the main or lobar bronchi are excluded; however, endobronchial lesions in the segmented bronchi are allowed.~ * Lesions extensively infiltrating the main or lobar bronchi are excluded; however, minor infiltrations in the wall of the bronchi are allowed.~* Recent hemoptysis (≥½ teaspoon of red blood within 8 weeks before first dose of study drug).~* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.~* Treatment with any of the following anti-cancer therapies:~  * radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR~ * chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib~* Administration of any non-oncologic investigational drug within 30 days or 5 half lives whichever is longer prior to receiving the first dose of study treatment~* Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: ACTIVE_COMPARATOR): 800mg, oral, 24 months
- Placebo (Type: PLACEBO_COMPARATOR): 800mg, oral, 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).